title: [Treatment of tuberculosis].
abstract: The aim of this article is to give practicing physicians a practical approach to the treatment of latent and active tuberculosis. Most patients follow TB standard treatment recommended by WHO that depend on category of patient. It is a combination of four essential tuberculosis drugs of the first group: isoniazid, rifampicin, pyrazinamid and ethambutol; in some cases streptomycin can replace ethambutol. This initial phase of intensive treatment is followed by a consolidation phase. Drugs should be administered in the morning on an empty stomach one hour before meals. Treatment of latent tuberculosis (TB) infection is an important component of TB control programs. Preventive treatment can reduce the risk of developing active TB.
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie. Electronic address: jihenbenamar@gmail.com.
authors.forename: J
authors.initials: J
authors.lastname: Ben Amar
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: B
authors.initials: B
authors.lastname: Dhahri
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: H
authors.initials: H
authors.lastname: Aouina
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: S
authors.initials: S
authors.lastname: Azzabi
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: M A
authors.initials: MA
authors.lastname: Baccar
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: L
authors.initials: L
authors.lastname: El Gharbi
authors.affiliation: Service de pneumologie, hôpital Charles-Nicolle, faculté de médecine de Tunis, université Tunis El Manar, Tunis, Tunisie.
authors.forename: H
authors.initials: H
authors.lastname: Bouacha
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D055985:Latent Tuberculosis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
keywords: Latent tuberculosis; Traitement; Treatment; Tuberculose; Tuberculose latente; Tuberculosis